ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 16 of 32 for:    "Pneumonia, Pneumococcal"

Phase I to Test a New Pneumococcal Vaccine

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03303976
Recruitment Status : Active, not recruiting
First Posted : October 6, 2017
Last Update Posted : November 17, 2017
Sponsor:
Information provided by (Responsible Party):
LimmaTech Biologics AG

Brief Summary:

To obtain first-in-human data on a new candidate vaccine against Streptococcus pneumoniae in healthy adult and elderly volunteers.

The study aims to assess the safety and immunogenicity of a bioconjugate investigational vaccine compared to the control group (Pneumovax23).


Condition or disease Intervention/treatment Phase
Pneumococcal Pneumonia Pneumonia, Bacterial Biological: Bioconjugate pneumococcal vaccine Biological: Multivalent plain polysaccharide vaccine Phase 1

Detailed Description:
The study aims to assess the safety and immunogenicity of a new bioconjugate investigational vaccine compared to the control group (Pneumovax23) in a randomised, staggered, 2-steps controlled trial.

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 70 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Participant)
Primary Purpose: Prevention
Official Title: Safety and Immunogenicity of a Candidate Bioconjugate Vaccine Against Streptococcus Pneumoniae When Administered to Adult and Elderly Healthy Subjects. A Phase I Randomized Study.
Actual Study Start Date : September 7, 2017
Estimated Primary Completion Date : May 2018
Estimated Study Completion Date : June 2018

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Pneumonia

Arm Intervention/treatment
Experimental: Pneumo1-low dose
Arm A: intramuscular injection monovalent bioconjugate pneumococcal vaccine
Biological: Bioconjugate pneumococcal vaccine
Bioconjuagte vaccine against bacterial pneumococcal infection

Experimental: Pneumo1-mid dose
Arm B: intramuscular injection monovalent bioconjugate pneumococcal vaccine
Biological: Bioconjugate pneumococcal vaccine
Bioconjuagte vaccine against bacterial pneumococcal infection

Experimental: Pneumo1-target dose
Arm C: intramuscular injection monovalent bioconjugate pneumococcal vaccine
Biological: Bioconjugate pneumococcal vaccine
Bioconjuagte vaccine against bacterial pneumococcal infection

Active Comparator: Pneumovax23
Arm D: intramuscular injection multivalent plain polysaccharide vaccine
Biological: Multivalent plain polysaccharide vaccine
Multivalent plain polysaccharide vaccine against bacterial pneumococcal infection




Primary Outcome Measures :
  1. Incidence of adverse events [ Time Frame: until one month after injection ]
    Safety and tolerability of the candidate vaccine as determined by occurrence, severity, relationship, of solicited and unsolicited advers events (AEs) and serious adverse events (SAEs) after injection of the candidate vaccine compared to the control group throughout the study until one month after injection.


Secondary Outcome Measures :
  1. Clinical laboratory abnormality measure [ Time Frame: change from baseline one week after injection and one month after injection ]
    Safety of the candidate vaccine by measuring changes in haematological and biochemical safety parameters before injection (baseline) and after vaccine administration, in terms of absolute changes and between groups.

  2. Assess immunogenicity of the candidate vaccine [ Time Frame: one month and six months after injection ]
    Evaluation of antigen-specific antibodies levels and functionality at each time point for all groups in terms of change from baseline



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   60 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Male or female between 60 and 70 (inclusive) years of age at the time of vaccination.
  • Subject who is willing and able to comply with the requirements of the protocol (e.g. completion of the diary cards, return for follow-up visits).
  • Signed informed consent obtained from the subject.

Exclusion Criteria:

  • Health condition that, in the opinion of the investigator, may interfere with optimal participation in the study or place the volunteer at increased risk of adverse events (AEs). Study clinicians, in consultation with the principal investigator, will use clinical judgment on a case-by-case basis to assess safety risks under this criterion. The PI will consult with the medical monitor as appropriate. • Clinically significant abnormalities on physical examination.
  • Clinically significant abnormalities on laboratory screening.
  • Acute or chronic, clinically significant cardiovascular, pulmonary, hepatic or renal abnormality, diseases and/or insufficiency as determined by physical examination or laboratory tests, in particular: unstable current or history of coronary artery disease or cardiac insufficiency, uncontrolled hypertension, clinically significant history of myocardial infarction, atrial fibrillation, uncontrolled or clinically significant type 2 diabetes, current or history of rheumatoid arthritis or temporal arteritis, current acute or chronic active pulmonary diseases.
  • Planned administration of a vaccine not foreseen by the study protocol within 4 weeks before and after the vaccination.
  • Previous vaccination with any licensed or investigational pneumococcal vaccine or planned administration of a pneumococcal vaccination not foreseen by the study protocol and during the study period, as reported by subject.
  • History of radiologically documented pneumonia or invasive pneumococcal disease (IPD) within 3 years previous to study start, as reported by subject.
  • Known hypersensitivity to any components of the pneumococcal conjugate vaccine.
  • Previous vaccination with any pseudomonas investigational vaccine as reported by the subject.
  • Known or suspected impairment of immunological function, documented Human Immunodeficiency Virus (HIV) infection, asplenia, or history of autoimmune disease.
  • History of regular use (>2 weeks) in the last 6 months of immunosuppressive drugs including systemic corticosteroids (e.g. corticosteroids ≥0.5 mg/kg BW/day, excluding inhaled and topical steroid).
  • Has a coagulation disorder contraindicating intramuscular vaccination..
  • Received or receiving immunosuppressive therapy, including chemotherapeutic agents used to treat cancer or other conditions, and treatments associated with organ or bone marrow transplantation or autoimmune disease.
  • Received a blood transfusion or previous treatment with blood products, including immunoglobulins within the 3 months preceding the injection, or is scheduled to receive them within 30 days after vaccination.
  • Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine(s) within 3 months preceding the administration of study vaccine, or planned use during the study period.
  • BMI (Body Mass Index) <19 or ≥35.
  • Positive blood test for HBsAg, hepatitis C virus (HCV), HIV-1/2.
  • History of allergy to any vaccine.
  • Use of any antibiotic therapy within 1 week preceding injection.
  • Subjects with an elective surgical intervention, planned during the study period.
  • History of chronic alcohol consumption and/or drug abuse.
  • Blood donation of at least 500 mL blood draw within 3 months preceding injection or planned during the study period as reported by subject.
  • Pregnancy or intention to become pregnant as reported by subject.
  • Female subjects who are not postmenopausal for at least 2 years.
  • Man subjects with a female partner in reproductive age refusing to use contraception methods.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03303976


Locations
Germany
CRS
Mönchengladbach, Germany
Sponsors and Collaborators
LimmaTech Biologics AG
Investigators
Principal Investigator: Michael Leidig, MD CRS Mönchengladbach

Responsible Party: LimmaTech Biologics AG
ClinicalTrials.gov Identifier: NCT03303976     History of Changes
Other Study ID Numbers: Pneumo1
First Posted: October 6, 2017    Key Record Dates
Last Update Posted: November 17, 2017
Last Verified: November 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by LimmaTech Biologics AG:
pneumococcal vaccine
bioconjugate

Additional relevant MeSH terms:
Pneumonia, Pneumococcal
Pneumonia
Pneumonia, Bacterial
Lung Diseases
Respiratory Tract Diseases
Respiratory Tract Infections
Bacterial Infections
Pneumococcal Infections
Streptococcal Infections
Gram-Positive Bacterial Infections
Vaccines
Heptavalent Pneumococcal Conjugate Vaccine
Immunologic Factors
Physiological Effects of Drugs